Anavex OKd for U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

 Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024

Trial to include Schizophrenia validated clinical outcomes PANSS and EEG/ERP biomarkers

Trial to study positive, negative, and cognitive domains of Schizophrenia based on ANAVEX®3-71’s ability to synergistically activate both SIGMAR1 and M1 muscarinic receptors

https://www.globenewswire.com/news-release/2024/01/16/2809762/29248/en/Anavex-Life-Sciences-Announces-U-S-Phase-2-Clinical-Trial-of-ANAVEX-3-71-in-Schizophrenia.html